197 related articles for article (PubMed ID: 26915677)
1. Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.
Horak F; Puri KD; Steiner BH; Holes L; Xing G; Zieglmayer P; Zieglmayer R; Lemell P; Yu A
J Allergy Clin Immunol; 2016 Jun; 137(6):1733-1741. PubMed ID: 26915677
[TBL] [Abstract][Full Text] [Related]
2. Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure.
Badorrek P; Müller M; Koch W; Hohlfeld JM; Krug N
Ann Allergy Asthma Immunol; 2017 Mar; 118(3):290-297. PubMed ID: 28284536
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.
Krug N; Gupta A; Badorrek P; Koenen R; Mueller M; Pivovarova A; Hilbert J; Wetzel K; Hohlfeld JM; Wood C
J Allergy Clin Immunol; 2014 Feb; 133(2):414-9. PubMed ID: 24332218
[TBL] [Abstract][Full Text] [Related]
4. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.
Stuebner P; Horak F; Zieglmayer R; Arnáiz E; Leuratti C; Pérez I; Izquierdo I
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):37-44. PubMed ID: 16440531
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Ellis AK; Tsitoura DC; Quint D; Powley W; Lee LA
Clin Exp Allergy; 2017 Sep; 47(9):1193-1203. PubMed ID: 28681506
[TBL] [Abstract][Full Text] [Related]
6. Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals.
Shamji MH; Bellido V; Scadding GW; Layhadi JA; Cheung DK; Calderon MA; Asare A; Gao Z; Turka LA; Tchao N; Togias A; Phippard D; Durham SR
Allergy; 2015 Feb; 70(2):171-9. PubMed ID: 25377909
[TBL] [Abstract][Full Text] [Related]
7. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.
Horak F; Zieglmayer P; Zieglmayer R; Lemell P; Collins LP; Hunter MG; Steiner J; Lewis T; Payton MA; Perkins CM; Pettipher R
Allergy; 2012 Dec; 67(12):1572-9. PubMed ID: 23025511
[TBL] [Abstract][Full Text] [Related]
8. Regulation of melanocortin 1 receptor in allergic rhinitis in vitro and in vivo.
Kleiner S; Braunstahl GJ; Rüdrich U; Gehring M; Eiz-Vesper B; Luger TA; Steelant B; Seys SF; Kapp A; Böhm M; Hellings PW; Raap U
Clin Exp Allergy; 2016 Aug; 46(8):1066-74. PubMed ID: 27196703
[TBL] [Abstract][Full Text] [Related]
9. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
10. Rhinitis symptoms caused by grass pollen are associated with elevated basophile allergen sensitivity and a larger grass-specific immunoglobulin E fraction.
Zidarn M; Košnik M; Silar M; Grahek A; Korošec P
Clin Exp Allergy; 2012 Jan; 42(1):49-57. PubMed ID: 22093044
[TBL] [Abstract][Full Text] [Related]
11. Distinct Contributory Factors Determine Basophil-Allergen Sensitivity in Grass Pollen Rhinitis and in Anaphylactic Wasp Venom Allergy.
Korošec P; Šilar M; Kopač P; Eržen R; Zidarn M; Košnik M
Int Arch Allergy Immunol; 2016; 171(2):89-101. PubMed ID: 27907922
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber.
Zieglmayer P; Zieglmayer R; Bareille P; Rousell V; Salmon E; Horak F
Curr Med Res Opin; 2008 Jun; 24(6):1833-40. PubMed ID: 18498678
[TBL] [Abstract][Full Text] [Related]
13. Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo-controlled crossover park study.
Kenney P; Hilberg O; Laursen AC; Peel RG; Sigsgaard T
J Allergy Clin Immunol; 2015 Dec; 136(6):1566-1572.e5. PubMed ID: 26141263
[TBL] [Abstract][Full Text] [Related]
14. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
16. Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
Krug N; Hohlfeld JM; Geldmacher H; Larbig M; Heermann R; Lavallee N; Nguyen DT; Petzold U; Hermann R
Allergy; 2005 Mar; 60(3):354-9. PubMed ID: 15679722
[TBL] [Abstract][Full Text] [Related]
17. IgE+ B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis.
Wong KJ; Timbrell V; Xi Y; Upham JW; Collins AM; Davies JM
Allergy; 2015 Apr; 70(4):420-8. PubMed ID: 25556717
[TBL] [Abstract][Full Text] [Related]
18. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.
Greiff L; Persson CG; Andersson M
Ann Allergy Asthma Immunol; 2002 Oct; 89(4):413-8. PubMed ID: 12392387
[TBL] [Abstract][Full Text] [Related]
19. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study.
Rimmer J; Peake HL; Santos CM; Lean M; Bardin P; Robson R; Haumann B; Loehrer F; Handel ML
Clin Exp Allergy; 2007 Jan; 37(1):8-14. PubMed ID: 17210036
[TBL] [Abstract][Full Text] [Related]
20. Basophil activation test for inhalant allergens in pediatric patients with allergic rhinitis.
Ogulur I; Kiykim A; Baris S; Ozen A; Yuce EG; Karakoc-Aydiner E
Int J Pediatr Otorhinolaryngol; 2017 Jun; 97():197-201. PubMed ID: 28483235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
